1. Home
  2. BOW vs DRUG Comparison

BOW vs DRUG Comparison

Compare BOW & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bowhead Specialty Holdings Inc.

BOW

Bowhead Specialty Holdings Inc.

HOLD

Current Price

$33.75

Market Cap

734.3M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$64.14

Market Cap

778.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOW
DRUG
Founded
2020
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
734.3M
778.4M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
BOW
DRUG
Price
$33.75
$64.14
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$32.29
$129.25
AVG Volume (30 Days)
298.1K
93.1K
Earning Date
05-05-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
23.26
N/A
EPS
0.96
N/A
Revenue
$551,589,000.00
N/A
Revenue This Year
$21.31
N/A
Revenue Next Year
$19.15
N/A
P/E Ratio
$35.04
N/A
Revenue Growth
29.58
N/A
52 Week Low
$21.21
$44.25
52 Week High
$35.07
$123.75

Technical Indicators

Market Signals
Indicator
BOW
DRUG
Relative Strength Index (RSI) 59.02 33.86
Support Level $24.07 $64.82
Resistance Level $33.93 $78.35
Average True Range (ATR) 0.13 3.17
MACD -0.12 -1.39
Stochastic Oscillator 31.11 9.37

Price Performance

Historical Comparison
BOW
DRUG

About BOW Bowhead Specialty Holdings Inc.

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: